A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus

NCT07405970 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

316

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: MIL62
DRUG: Placebo

Sponsor

Beijing Mabworks Biotech Co., Ltd.